Unable to load price data. Sorry.

¯\_(ツ)_/¯

Molecular Insight Pharmaceuticals, Inc. (NASDAQOTH:MIPIQ)

CAPS Rating: No stars

A biopharmaceutical company focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics designed to improve patient diagnosis, treatment and management.

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

24 Outperform
10 Underperform
 

All-Star Players

4 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQOTH:MIPIQ Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Justin5342002 (81.43)
Submitted August 12, 2007

The company currently has no drugs on the market which I would imagine no product on the market + expenses = low or declining stock price short term, however,Their two oncology drugs Azedra and Onalta both have orphan drug status which will allow… More

cashsage (99.31)
Submitted November 18, 2009

MIPI has a too high valuation compared to its sales potential. It is also very loss making at least until 2011.

Recent Community Commentary

Read the most recent pitches from players about MIPIQ.

Recs

0
Member Avatar ssimo2005 (< 20) Submitted: 6/19/2009 11:45:31 AM : Outperform Start Price: $6.09 NASDAQ OTHER:MIPIQ Score: -364.22

company is working on a new research "final fase"with own capital, once research is out. stock will boom

Recs

0
Member Avatar hennessy7 (< 20) Submitted: 5/31/2008 2:52:46 PM : Outperform Start Price: $7.00 NASDAQ OTHER:MIPIQ Score: -247.17

Like the sector and recent buying.

Recs

2
Member Avatar Justin5342002 (81.43) Submitted: 8/11/2007 8:26:38 PM : Outperform Start Price: $7.69 NASDAQ OTHER:MIPIQ Score: -239.49

The company currently has no drugs on the market which I would imagine no product on the market + expenses = low or declining stock price short term, however,

Their two oncology drugs Azedra and Onalta both have orphan drug status which will allow greater profits for a longer period of time once (if) they receive FDA approval.

Also, Azedra has fast track approval as well along with its orphan drug status.

I just ran a few numbers to see what kind of potential revenue they could generate from treating neuroendicrine cancer, which is what their current oncology drugs are primarily geared towards. Please feel free to refute my numbers as well if anyone feels they are off which they very well could be...

Anyways, It looks like there are roughly 9,000 new cases of neuroendicrine cancer each year. Those are new cases but for the case of this rationale lets just say there are only 9,000 people to treat in the United States each year. Now lets say Azedra and Onalta can only be applied to 1/3rd of that population. So we have 3000 people to treat each year. Now, I dont know how much conventional chemotherapy costs but I'll make an estimate that chemo drugs on average cost roughly $10,000 for any given treatment for one person in a three month period (or one fiscal quarter). And I think I might be under estimating the costs of chemo here.

Now lets say MIPI charges the same amount for their treatments, so $10,000 each fiscal quarter approximately for the medication per person. Again I think Im underestimating costs as Onalta and Azedra is a radically different technology than traditional chemotherapy, but just for the sake of argument lets stick with my assumptions.

Now we have 3000 people to be treated at $10,000 each for each fiscal quarter. That is $30,000,000 in revenue each quarter and $120,000,000 in revenue each year.

MIPIs current market cap is only $185 million, which means in one year MIPI could potentially generate revenues pretty darn close to their current market cap once their cancer drugs come to market. I also didnt even consider any revenues for Zemiva either, another drug in their pipeline for detection of cardiac ischemias. On top of that I only considered a US population, tried to underestimate all my numbers as far as who would get treatment, and the cost of Onalta and Azedra.

Leaderboard

Find the members with the highest scoring picks in MIPIQ.

Score Leader

adambward

adambward (73.82) Score: +367.30

The Score Leader is the player with the highest score across all their picks in MIPIQ.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
adambward 73.82 6/18/2009 Underperform 3W $6.95 -99.94% +267.36% +367.30 0 Comment
SirCharms < 20 6/10/2009 Underperform 5Y $4.47 -99.91% +252.80% +352.71 0 Comment
dexxyru < 20 11/2/2009 Underperform 5Y $4.35 -99.91% +221.96% +321.87 0 Comment
anticitrademix < 20 11/2/2009 Underperform 5Y $4.85 -99.92% +220.14% +320.05 0 Comment
anticitrademix2 < 20 11/2/2009 Underperform 5Y $4.85 -99.92% +220.14% +320.05 0 Comment
payroll1 82.49 5/12/2008 Underperform 5Y $7.35 -99.94% +148.27% +248.21 0 Comment
sac3 69.38 8/23/2007 Underperform NS $6.90 -99.94% +138.17% +238.11 0 Comment
Styex < 20 7/31/2007 Underperform NS $8.00 -99.95% +136.58% +236.53 0 Comment
phalayko 94.60 9/28/2007 Underperform 3M $6.82 -99.94% +128.50% +228.44 0 Comment
crossbreed 65.88 7/13/2007 Underperform 1Y $9.12 -99.96% +127.03% +226.99 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MIPIQ.